Omada Health/$OMDA
1D1W1MYTD1Y5YMAX
Capital at risk
About Omada Health
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
- Ticker
- $OMDA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 946
- Headquarters
- South San Francisco, United States
- Website
- www.omadahealth.com
Omada Health Metrics
BasicAdvanced
$1.3B
278.76
$0.07
-
-
Price and volume
Market cap
$1.3B
52-week high
$26.92
52-week low
$10.28
Average daily volume
1.5M
Financial strength
Current ratio
3.907
Quick ratio
3.7
Interest coverage (TTM)
-1.17%
Profitability
EBITDA (TTM)
5.431
Gross margin (TTM)
68.19%
Net profit margin (TTM)
1.39%
Operating margin (TTM)
-0.15%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-0.09%
Return on equity (TTM)
1.84%
Valuation
Price to earnings (TTM)
278.756
Price to revenue (TTM)
3.874
Price to book
4.9
Price to tangible book (TTM)
5.2
Price to free cash flow (TTM)
70.05
Free cash flow yield (TTM)
1.43%
Free cash flow per share (TTM)
0.292
Growth
Revenue change (TTM)
47.63%
Earnings per share change (TTM)
-102.61%
What the Analysts think about Omada Health
Analyst ratings (Buy, Hold, Sell) for Omada Health stock.
Analyst projections of the future price of Omada Health stock.
Bulls say / Bears say
Omada’s Q2 revenue rose 43% year on year, members grew 45% to 1.1 million, and it reported its first quarterly net profit. It also raised 2026 revenue guidance to $334 million–$340 million and adjusted EBITDA guidance to $21 million–$27 million. (Omada Health)
Omada has widened distribution for its GLP-1 Care Track through all three major pharmacy benefit managers and a direct-to-employer partnership with Eli Lilly. Those channels could help it use weight-management demand to sell broader cardiometabolic care. (Omada Health, Omada Health)
At its investor day, Omada set a long-term target of at least 20% annual revenue growth, 80% non-GAAP gross margin and a 30% adjusted EBITDA margin. Its recent member growth and margin expansion suggest that scale, AI-enabled automation and a richer product mix could create substantial operating leverage. (Omada Health)
A large share of revenue remains concentrated in two Cigna-affiliated partners: each contributed 33% of Q1 2026 revenue. Losing or weakening either relationship could therefore have a material effect on growth and cash collection. (StockTitan)
The planned change from co-founder Sean Duffy as chief executive to Wei-Li Shao on 1 January 2027 adds execution risk just as Omada is scaling quickly. The transition could unsettle customers, staff or investors if the new leadership does not maintain the current growth and margin trajectory. (Omada Health)
The shares are priced for strong execution, with a reported trailing P/E above 260 times and a forward P/E above 40 times. If revenue growth, GLP-1 adoption or margin expansion falls short of expectations, that premium leaves considerable scope for a valuation reset. (StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 19 Sept 2026.
Omada Health Financial Performance
Revenues and expenses
Omada Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Omada Health News
AllArticlesVideos
Funds containing Omada Health
AllEURUSDGBP
Fund name | Fund size | $OMDA weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.01% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.